Opus Genetics secures up to $155M debt facility from Oberland Capital; cash runway extended into 2029

Opus Genetics, Inc.

$155M senior secured notes: $35M initial (closing Apr 20, 2026), $35M option in 12 mos, $35M milestone-based (LCA5), $50M mutual agreement.
$5M equity investment at $4.48/share; 1,116,070 shares issued to Oberland affiliates.
Notes mature Apr 2033; floating rate (SOFR + margin, 3.68% floor); 50% PIK first 8 quarters; 10% convertible at $6.72/share.
Cash ~$100M including initial funding; runway extended into 2029 through pivotal studies and potential approvals.
Pipeline acceleration: OPGx-RDH12 (Q4 2026), OPGx-MERTK (end 2026), OPGx-RHO (2027) entering clinic.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Opus Genetics, Inc. entered into Note Purchase Agreement with OPCM SA LLC valued at up to $155 million (effective 2026-04-02).

Action: entry
Agreement: notes offering
Counterparty: OPCM SA LLC
Value: up to $155 million
Effective: 2026-04-02

Exact text from the filing

On April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agreement (the “Note Purchase Agreement”) with OPCM SA LLC, as purchaser agent (“Purchaser Agent”), and certain purchasers party thereto (the “Purchasers”).

View on SEC.gov

Browse all material agreements →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-013394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.